Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Guanidine
A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.
Year introduced: 1998
guanidine carboxamide [Supplementary Concept]
RN given refers to parent cpd
Date introduced: May 14, 1981
NC 174 [Supplementary Concept]
a trisubstituted guanidine high potency sweetener; structure given in first source
Date introduced: November 10, 1993
1-(4-iodophenyl)-3-(1-adamantyl)guanidine [Supplementary Concept]
structure given in first source
Date introduced: January 26, 1993
1,3-ditolylguanidine [Supplementary Concept]
structure given in first source; a selective ligand for the sigma binding sites in the brain
Date introduced: December 15, 1986
N,N-dimethyl-N-(3-chlorophenyl)guanidine [Supplementary Concept]
Date introduced: January 1, 1977
3-Iodobenzylguanidine
A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
N-(4-(1-acetyl-piperidin-4-yl)-3-trifluoromethylbenzoyl)guanidine [Supplementary Concept]
a sodium hydrogen exchanger isoform 1 (NHE1) inhibitor; structure in first source
Date introduced: November 25, 2012
N-(3,4-dichlorophenyl)-N'-isopropyl-N'-(1-isopropyl-1H-imidazol-2-yl)guanidine [Supplementary Concept]
an antimalarial; structure in first source
Date introduced: December 11, 2011
N-(4-fluorobenzoyl)-N'-(2-(5-(4-fluorobenzyl)-1-(4-methoxybenzyl)-4,6-dioxo-1,4,5,6-tetrahydro(1,3,5)triazin-2-ylamino)ethyl)guanidine [Supplementary Concept]
a prokineticin receptor 1 antagonist; structure in first source
Date introduced: May 29, 2011
(1-((5-methyl-3-(2-methylsulfonylphenylsulfonyloxy)phenoxyl)methyl) cyclopropylmethoxy)guanidine hydrochloride [Supplementary Concept]
anticoagulant; text has a typo quanidine for guanidine; structure in first source
Date introduced: July 18, 2008
(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine [Supplementary Concept]
KR-32570 possesses potent cardioprotective effects in perfused rat hearts, and its effects may be mediated by inhibition of NHE-1, preservation of high-energy phosphates, and inhibition of lipid peroxidation
Date introduced: July 25, 2005
N,N'-bis(4-chlorobenzylideneamino)guanidine [Supplementary Concept]
an antiprotozoan agent; structure in first source
Date introduced: September 25, 2004
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine [Supplementary Concept]
inhibits sodium hydrogen exchanger NHE-1; structure in first source
Date introduced: February 18, 2004
dinotefuran [Supplementary Concept]
structure in first source
Date introduced: September 18, 2002
(7-(5-fluoro-2-methylphenyl)-4-methyl-7,8-dihydro-5(6H)-quinolinylideneamino)guanidine [Supplementary Concept]
an inhibitor of Na(+)/H(+)-exchanger isoform NHE1; structure in first source
Date introduced: August 23, 2001
zoniporide [Supplementary Concept]
inhibits sodium-hydrogen exchanger isoform-1 (NHE-1)
Date introduced: April 25, 2001
N-(4-chlorobenzyl)-N-(6-pyrrolidin-1-ylhexyl)guanidine [Supplementary Concept]
Date introduced: July 21, 2000
N-(4-chlorobenzyl)-N-(7-pyrrolidin-1-ylheptyl)guanidine [Supplementary Concept]
N-nitro-N'-(1-(2,3,5-tri-O-acetyl-erythro-pentofuranosyl)-2,4-dioxoimidazolidin-5-ylidene)guanidine [Supplementary Concept]
Date introduced: July 7, 2000